Keppra
Schizophreniform
NYU Langone HealthPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Schizophreniform cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Acetyl-L-Cysteine University of Maryland, Baltimore | Phase 4 | BBB |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →